| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Company Name: |
SPIRO PHARMA |
| Tel: |
|
| Email: |
eric_feng1954@126.com |
|
| | PyriMido[5',4':5,6]pyriMido[1,2-a]benziMidazol-5(6H)-one, 6-(2,6-diMethylphenyl)-2-[[4-(4-Methyl-1-piperazinyl)phenyl]aMino]- Basic information |
| Product Name: | PyriMido[5',4':5,6]pyriMido[1,2-a]benziMidazol-5(6H)-one, 6-(2,6-diMethylphenyl)-2-[[4-(4-Methyl-1-piperazinyl)phenyl]aMino]- | | Synonyms: | PyriMido[5',4':5,6]pyriMido[1,2-a]benziMidazol-5(6H)-one, 6-(2,6-diMethylphenyl)-2-[[4-(4-Methyl-1-piperazinyl)phenyl]aMino]-;Lck Inhibitor;6-(2,6-Dimethylphenyl)-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-one;6-(2,6-Dimethylphenyl)-2-[[4-(4-methyl-1-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-one;TC-S 7003 (Lck Inhibitor);Lck Inhibitor 25;6-(2,6-Dimethylphenyl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)benzo[4,5]imidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-one | | CAS: | 847950-09-8 | | MF: | C31H30N8O | | MW: | 530.62 | | EINECS: | | | Product Categories: | | | Mol File: | 847950-09-8.mol | ![PyriMido[5',4':5,6]pyriMido[1,2-a]benziMidazol-5(6H)-one, 6-(2,6-diMethylphenyl)-2-[[4-(4-Methyl-1-piperazinyl)phenyl]aMino]- Structure](CAS/GIF/847950-09-8.gif) |
| | PyriMido[5',4':5,6]pyriMido[1,2-a]benziMidazol-5(6H)-one, 6-(2,6-diMethylphenyl)-2-[[4-(4-Methyl-1-piperazinyl)phenyl]aMino]- Chemical Properties |
| Boiling point | 809.1±75.0 °C(Predicted) | | density | 1.36±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | crystalline solid | | pka | 7.87±0.42(Predicted) | | color | Light yellow to yellow |
| | PyriMido[5',4':5,6]pyriMido[1,2-a]benziMidazol-5(6H)-one, 6-(2,6-diMethylphenyl)-2-[[4-(4-Methyl-1-piperazinyl)phenyl]aMino]- Usage And Synthesis |
| Uses | TC-S 7003 is a novel, potent and orally active inhibitor of Lymphocyte Specific Kinase (Lck). | | in vivo | Lck inhibitor (0-60 mg/kg; oral once daily; from day 9 to day 17) showed a dose-dependent inhibition of arthritis[1]. Lck inhibitor (5 mg/kg oral) treatment showed Cmax, AUC0-∞, tmax, and F% were 82 ng/mL, 862 ng h/mL, and 17%, respectively[1]. | Animal Model: | Male Lewis rat (adjuvant-inducedarthritis model) [1] | | Dosage: | 0, 30, and 60 mg/kg | | Administration: | Po; once daily; from day 9 today 17 | | Result: | Showed a dose-dependent inhibition of arthritis, with an ED50 estimated at 24 mg/kg. |
| Animal Model: | Sprague-Dawley Rats[1] | | Dosage: | Po (Pharmacokinetic Analysis) | | Administration: | 5 mg/kg | | Result: | The Cmax, AUC0-∞, tmax and F% were 82 ng/mL, 862 ng h/mL, and 17%, respectively. |
| | storage | Store at -20°C |
| | PyriMido[5',4':5,6]pyriMido[1,2-a]benziMidazol-5(6H)-one, 6-(2,6-diMethylphenyl)-2-[[4-(4-Methyl-1-piperazinyl)phenyl]aMino]- Preparation Products And Raw materials |
|